Wall Street analysts expect that Karyopharm Therapeutics Inc (NASDAQ:KPTI) will post earnings of ($0.88) per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Karyopharm Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.80) and the lowest estimate coming in at ($0.94). Karyopharm Therapeutics posted earnings per share of ($0.65) in the same quarter last year, which would indicate a negative year-over-year growth rate of 35.4%. The business is scheduled to issue its next quarterly earnings report before the market opens on Thursday, November 8th.
According to Zacks, analysts expect that Karyopharm Therapeutics will report full-year earnings of ($3.18) per share for the current financial year, with EPS estimates ranging from ($3.36) to ($2.96). For the next financial year, analysts forecast that the company will post earnings of ($3.18) per share, with EPS estimates ranging from ($3.84) to ($2.55). Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Karyopharm Therapeutics.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Tuesday, August 7th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.81) by $0.21. The company had revenue of $19.89 million during the quarter, compared to analyst estimates of $5.97 million.
NASDAQ:KPTI traded up $0.02 during trading hours on Tuesday, reaching $11.24. The company had a trading volume of 563,180 shares, compared to its average volume of 1,214,573. Karyopharm Therapeutics has a 1-year low of $9.00 and a 1-year high of $21.71. The company has a market capitalization of $680.73 million, a PE ratio of -4.00 and a beta of 3.93.
In other news, Director Mansoor Raza Mirza sold 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 29th. The stock was sold at an average price of $20.00, for a total transaction of $50,000.00. Following the completion of the transaction, the director now directly owns 2,500 shares of the company’s stock, valued at approximately $50,000. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Sharon Shacham sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, October 18th. The stock was sold at an average price of $12.63, for a total value of $126,300.00. Following the transaction, the insider now directly owns 713,510 shares of the company’s stock, valued at $9,011,631.30. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 827,266 shares of company stock valued at $16,495,001. Corporate insiders own 13.26% of the company’s stock.
Several hedge funds have recently made changes to their positions in KPTI. UBS Group AG raised its stake in shares of Karyopharm Therapeutics by 761.8% during the 1st quarter. UBS Group AG now owns 19,632 shares of the company’s stock worth $264,000 after buying an additional 17,354 shares during the period. Fox Run Management L.L.C. acquired a new position in shares of Karyopharm Therapeutics during the 3rd quarter worth approximately $266,000. Metropolitan Life Insurance Co. NY raised its stake in shares of Karyopharm Therapeutics by 38.9% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 16,275 shares of the company’s stock worth $277,000 after buying an additional 4,556 shares during the period. Voya Investment Management LLC raised its stake in shares of Karyopharm Therapeutics by 24.3% during the 2nd quarter. Voya Investment Management LLC now owns 18,661 shares of the company’s stock worth $317,000 after buying an additional 3,653 shares during the period. Finally, California Public Employees Retirement System acquired a new position in shares of Karyopharm Therapeutics during the 2nd quarter worth approximately $339,000. 71.84% of the stock is owned by institutional investors and hedge funds.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
Featured Story: How to Invest in a Bull Market
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.